Lifeboat Foundation

The Hubble Space Telescope has revealed a single star whose light has traveled for 12.9 billion years to Earth, having come from a universe just 900 million years old. It’s currently the most distant star known, and the team has dubbed it Earendel*.

The discovery is a huge jump, as the previous record-holder for more distant star existed in a universe 4 billion years old.

The iconic observatory had some help from nature’s own optics: The vast mass of a foreground cluster of galaxies, sitting just so between us and the distant star, acts like a lens, its gravity magnifying the star’s light thousands-fold. The discovery is published in the March 31st Nature.

China’s exclusive Alder Lake chip targets internet cafes.

Intel’s elusive ‘Black Edition’ Core i5-12490F is a China exclusive, but we snagged a chip we found overseas and put it through our benchmark suite.

Researchers uncover an ongoing large-scale supply-chain attack which exploits dependency confusion attacks against the NPM package repository.

A group of academics has designed a new system known as “Privid” that enables video analytics in a privacy-preserving manner.

A group of academics has designed a new system known as “Privid” that enables video analytics in a privacy-preserving manner.

Hackers using a “complex and powerful” malware loader with the ultimate objective of deploying cryptocurrency miners on compromised systems.

Researchers have uncovered a new malware campaign spreading Mars info-stealer via Google ads.

Researchers have uncovered a new malware campaign spreading Mars info-stealer via Google ads.

Reward maximisation is one strategy that works for reinforcement learning to achieve general artificial intelligence. However, deep reinforcement learning algorithms shouldn’t depend on reward maximisation alone.

Identifying dual-purpose therapeutic targets implicated in aging and disease will extend healthspan and delay age-related health issues.

AI is all that matters now, and reaching Agi before 2030 is all that matters for this decade.

A substantial percentage of the human clinical trials, including those evaluating investigational anti-aging drugs, fail in Phase II, a phase where the efficacy of the drug is tested. This poor success is in part due to inadequate target choice and the inability to identify a group of patients who will most likely respond to specific agents. This challenge is further complicated by the differences in the biological age of the patients, as the importance of therapeutic targets varies between the age groups. Unfortunately, most targets are discovered without considering patients’ age and being tested in a relatively younger population (average age in phase I is 24). Hence, identifying potential targets that are implicated in multiple age-associated diseases, and also play a role in the basic biology of aging, may have substantial benefits.

Identifying dual-purpose targets that are implicated in aging and disease at the same time will extend healthspan and delay age-related health issues – even if the target is not the most important in a specific patient, the drug would still benefit that patient.

Continue reading “Insilico identifies therapeutic targets implicated in aging using AI and hallmarks of aging framework” »

Imagine gliding into space in a pressurized capsule via a huge balloon the size of a football stadium. That’s how one startup plans to take tourists on suborbital journeys 100,000 feet above Earth.

Passengers will be able to observe stunning views during a six hour journey. They will also be able to sip on cocktails from a bar aboard the vessel. (Yes, there’s a bathroom.)

The voyage will happen “very gently and smoothly” and provide passengers “the quintessential astronaut experience,” Jane Poytner, co-founder and co-CEO of Space Perspective, told Yahoo Finance Live.